Disease · MONDO_0043373

sudden sensorineural hearing loss

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sudden sensorineural hearing loss. Diseases, record MONDO_0043373. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043373

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sudden sensorineural hearing loss; Open Targets
Open Targets ID: MONDO_0043373; Open Targets
MeSH: D003639; MeSH
Orphanet: ORPHA:90059; Orphanet
Highest stage of its drugs: Phase 3, for 5 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BRIMAPITIDE, C-TERMINAL ACID	CHEMBL4297348	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FOLIC ACID	CHEMBL1622	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE SODIUM SUCCINATE	CHEMBL1201081	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets47

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	7	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
CA2	Carbonic anhydrase 2	1	Carbonic anhydrase II inhibitor	Phase 2	https://conductscience.org/library/genes/760	Drugs and targets
CA4	Carbonic anhydrase 4	1	Carbonic anhydrase IV inhibitor	Phase 2	https://conductscience.org/library/genes/762	Drugs and targets
FGA	Fibrinogen	1	Fibrinogen hydrolytic enzyme	Phase 1/2	https://conductscience.org/library/genes/2243	Drugs and targets
FGB	Fibrinogen	1	Fibrinogen hydrolytic enzyme	Phase 1/2	https://conductscience.org/library/genes/2244	Drugs and targets
FGG	Fibrinogen	1	Fibrinogen hydrolytic enzyme	Phase 1/2	https://conductscience.org/library/genes/2266	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive modulator	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets

1 to 10 of 47

See all 47 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00097448	Sudden Deafness Treatment Trial	Phase 3	255	2013-04-04	Sudden Deafness	METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT02809118	Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment	Phase 3	56	2020-08-07	Hearing Loss, Idiopathic Sudden Sensorineural	BRIMAPITIDE, C-TERMINAL ACID	Its record names the disease	ClinicalTrials.gov
NCT02026479	Sudden Hearing Loss Multi-center Clinical Trial	Not applicable	300		Full-frequency Sudden Hearing Loss	DEXAMETHASONE PHOSPHORIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT02561091	AM-111 in the Treatment of Acute Inner Ear Hearing Loss	Phase 3	256		Hearing Loss	BRIMAPITIDE, C-TERMINAL ACID	Its record names the disease	ClinicalTrials.gov
NCT07134075	Intracochlear Injection of Glucocorticoid	Phase 2	150		Sudden Sensorineural Hearing Loss (SSNHL)	DEXAMETHASONE, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT07113158	Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss	Phase 3	142		Sudden Sensorineural Hearing Loss	ASPIRIN, FOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT05403229	The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss	Phase 2	140		Sudden Deafness, Sudden Sensorineural Hearing Loss	TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT07540728	Trans-round Window Membrane Intracochlear Steroid	Phase 2	108		Sudden Hearing Loss	DEXAMETHASONE, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT05623384	Effect of Ultrasound-guided Stellate Ganglion Block Combined With Facial Nerve and Glossopharyngeal Nerve Block on the Treatment of Sudden Deafness	Not applicable	90		Sudden Deafness	MECOBALAMIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT06467526	Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss	Phase 2	80		Sudden Hearing Loss	HYDROXYCHLOROQUINE, PREDNISOLONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Oral Steroids vs IT Steroids: serious adverse events	5 of 125	6 of 130	255	NCT00097448

Source Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41035311	DERIVED	1	PubMed
32698830	DERIVED	1	PubMed
22805100	DERIVED	1	PubMed
21610239	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043373

GET https://conductscience.org/api/diseases/v1/MONDO_0043373/targets?page=2

API reference For AI assistants